Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Frequently asked questions
What sector does Ultimovacs ASA (ULTI) operate in?
Ultimovacs ASA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Ultimovacs ASA (ULTI) current stock price?
As of the latest data, Ultimovacs ASA stock price is NOK 14.50, with a previous close of NOK 14.50.
What is Ultimovacs ASA (ULTI) current market capitalization?
Ultimovacs ASA market cap is approximately 498.89 million.
What is Ultimovacs ASA (ULTI) Earnings Per Share (EPS)?
The trailing EPS is -NOK 5.80.
Does Ultimovacs ASA (ULTI) pay dividends?
No. Ultimovacs ASA does not pay a dividend.
What is Ultimovacs ASA (ULTI) beta (volatility) score?
Ultimovacs ASA has a beta of 0.785, indicating lower volatility than the overall market.